<DOC>
	<DOCNO>NCT01117428</DOCNO>
	<brief_summary>This trial design multi-centre , open label , dose-escalation , phase I trial consist five part . Part A investigates safety PK escalate weekly dose Sym004 patient recurrent advance solid tumor . Part B C validate safety , PK efficacy weekly dose Sym004 MTD homogenous patient population advance mCRC wild-type KRAS . If MTD equal 12 mg/kg , part C explore 9 mg/kg level . Part B initiate safe dose establish Part A . Part D E validate safety , PK efficacy administer every 2 week dose 12 mg/kg 18 mg/kg , respectively . Part F validate safety , PK efficacy administer single loading dose 9 mg/kg follow weekly dos 6 mg/kg .</brief_summary>
	<brief_title>Sym004 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Part A : 1 . Patients refractory recurrent advance late stage solid tumor without available therapeutic option . Part B , C , D , E F : 1 . Patients refractory recurrent advance mCRC wildtype KRAS progress EGFR Ab treatment . 2 . Patients wit confirmed response treatment antiEGFR Ab treatment . 3 . Documented disease progression within 6 month cessation antiEGFR Ab treatment . 4 . Patients must willing biopsy perform tumor lesion screen Visit 6 . Part A , B , C , D , E F : 1 . Histologically cytologically confirm diagnosis cancer 2 . Failure and/or intolerance standard chemotherapy 3 . Life expectancy least 3 month 4 . ECOG performance status â‰¤2 1 . Patients clinically symptomatic brain metastasis . 2 . Received following treatment prior Visit 2 : Cytotoxic cytostatic anticancer chemotherapy within 4 week Total resection irradiation target lesion Antibody therapy within 4 week vaccine within 12 week Tyrosin kinase inhibitor within 4 week Any investigational agent within 4 week 3 . Diarrhea CTCAE &gt; 1 4 . Skin rash CTCAE &gt; 1 5 . Abnormal organ bone marrow function . 6 . Use immunosuppressive agent past 4 week prior trial start , include systemic corticosteroid use dos 20mg/day prednisolone equivalent . 7 . History malignancy within 5 year prior trial start , exception basal cell carcinoma skin carcinoma situ cervix ( Part A ) . 8 . Active severe infection , concurrent disease medical condition deem interfere conduct trial judge investigator . 9 . Known HIV positive 10 . Known active hepatitis B C 11 . Patients know uncontrolled allergic condition allergy study drug and/or component . 12 . Clinically significant cardiac disease include unstable angina , acute myocardial infarction within six month Visit 1 , congestive heart failure , arrhythmia require therapy , exception extra systole minor conduction abnormality control well treat chronic atrial fibrillation . 13 . Significant concurrent , uncontrolled medical condition evaluate investigator interfere effect trial drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Metastatic colorectal Cancer</keyword>
</DOC>